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There was very little information on the study sample. Most of the following information was obtained from the original effectiveness paper (see Other Publications of Related Interest).
The authors reported that they required 454 patients in order to achieve 80% power to detect significant differences between the treatments. They therefore aimed to recruit 500 patients so as to allow for a 10% dropout. The method of sample selection was not described. The initial sample was appropriate for the clinical study question as it included female patients with MBC. A total of 511 patients were recruited. Of these, 255 patients received the capecitabinedocetaxel combination and 256 received docetaxel alone. The median age was 52 years (range: 26 -79) in the combination group and 51 years (range: 25 -75) in the single-agent group. The authors did not report any refusal to participate, or specific exclusions.
Study design
There was very little information on the study design. Most of the following information was obtained from the original effectiveness paper (see Other Publications of Related Interest).
The analysis was based on a randomised, controlled clinical trial. The patients were randomised by country, using a block size of four, via a computer-assisted, touch-tone, central randomisation service located in Houston (TX, USA) and Brussels (Belgium). The patients were stratified according to whether they had received prior paclitaxel therapy. The patients were recruited from 75 centres in 16 countries. A minimum follow-up of 15 months was achieved in all patients. There was no loss to follow-up. Copies of the X-rays and computed tomography scans were given to a panel of radiologists for independent review. The radiologists were blinded to the study treatment, the clinical condition of the patient, and the investigator's evaluation.
Analysis of effectiveness
The basis of the analysis was intention to treat. The primary health outcome was tumour response. This was assessed at 6-week intervals until week 48 and then at 12-week intervals until disease progression. The best overall response achieved was reported. The patients were classified as achieving stable disease if, at the first tumour assessment after study treatment, there was neither disease progression nor a response that was later confirmed. Survival rates were also recorded. The authors reported that the baseline characteristics were well balanced between the two treatment groups.
Effectiveness results
The median time to disease progression was 6.1 months (95% confidence interval, CI: 5.4 -6.5) in the combination arm and 4.2 months (95% CI: 3.4 -4.5) in the single therapy arm. Therefore, combination therapy resulted in a significantly superior time to disease progression than single-agent therapy (logrank p=0.0001; hazard ratio 0.625, 95% CI: 0.545 -0.780).
The hazard ratio translates into a 35% decrease in the risk of disease progression with combined therapy.
The median survival was 14.5 months (95% CI: 12.3 -16.3) in the combination arm and 11.5 months (95% CI: 9.8 -12.7) in the single therapy arm.
The 12-month survival was 57% (95% CI: 51 -63) in the combination arm and 47% (95% CI: 41 -53) in the single therapy arm.
